曼恩凱德生物醫療 MNKD 深 滬
等待開盤 03-26 09:30:00 美东时间
2.28
-0.010
-0.44%
華盛通- 最 高2.45
- 今 開2.34
- 成交量 632.42万股
- 最 低 2.25
- 昨 收 2.29
- 總市值 7.02亿
- 52周最高 6.51
- 市盈率 靜 121.93
- 換手率 2.05%
- 52周最低 2.25
- 委 比 36.66%
- 總股本 3.08亿
- 歷史最高 57.40
- 量 比 0.64
- 振 幅 8.73%
- 歷史最低 0.666
- 每 手 1
- 風險率 0.93%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多MannKind CEO purchases 100,000 shares; stock climbs
MannKind(MNKD) chief executive officer and director, Michael Castagna reported buying 100,000 shares of company stock. The shares were purchased on March 10, 2026, at a price of $2.59 per share. The t...
03-11 22:00
United Therapeutics's board approves new $2B repurchase authorization; prices $1.5B ASR
United Therapeutics Corporation (UTHR) announced a stock repurchase program authorized by its board of directors, allowing for up to $2 billion in buybacks over the next year. The company has also sig...
03-09 19:37
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
MannKind Announces Settlement of Convertible Senior Notes
MannKind Corporation announced the settlement of $36.3 million in 2.50% convertible senior notes, tendered for conversion prior to the March 1, 2026 maturity date. The settlement on March 4, 2026 involved $35.5 million in cash and 569,023 MannKind common shares. MannKind, a biopharmaceutical company, focuses on innovative treatments for cardiometabolic and orphan lung diseases.
03-05 21:30
Liquidia FY 2025 Earnings Preview
Liquidia (LQDA) is scheduled to announce FY earnings results on Thursday, March 5th, before market open. The consensus EPS Estimate is -$0.62 (+62.7% Y/Y) and the consensus Revenue Estimate is $153.82...
03-04 23:37
MannKind to Attend Leerink Partners 2026 Global Healthcare Conference and Barclays 28th Annual Global Healthcare Conference
MannKind to Attend Leerink Partners 2026 Global Healthcare Conference and Barclays 28th Annual Global Healthcare Conference MannKind Corporation will attend the Leerink Partners 2026 Global Healthcare Conference in Miami on March 10, 2026 (3:40 p.m. ET) and the Barclays 28th Annual Global Healthcare
03-04 22:01
MannKind to Participate in Upcoming Investor Conferences
MannKind Corporation (Nasdaq: MNKD) announced its participation in two upcoming investor conferences in Miami. CEO Michael Castagna and CFO Chris Prentiss will engage in fireside chats and 1x1 meetings with investors. The events include the Leerink Partners 2026 Global Healthcare Conference on March 10 and the Barclays 28th Annual Global Healthcare Conference on March 11. Audio webcasts will be available on MannKind’s website, along with recordin...
03-04 14:00
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
What's Going On With MannKind Stock Friday?
MannKind Corp. (NASDAQ: MNKD) reported strong Q4 and FY 2025 results, with earnings and sales beating expectations.
02-28 01:30
HC Wainwright & Co. Maintains Buy on MannKind, Lowers Price Target to $8
HC Wainwright & Co. analyst Brandon Folkes maintains MannKind (NASDAQ:MNKD) with a Buy and lowers the price target from $11 to $8.
02-27 20:15
